Physician profile
Peter G Uggowitzer
NPI 1255333274
$1,729.62
in general payments reported to CMS, 2019-2025
20 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $166 · 2022: $658 · 2023: $170 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $303.03 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $261.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $202.70 | 2022-2023 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $186.55 | 2019-2020 | |
| Novo Nordisk INC | $105.26 | 2019-2022 | |
| Pfizer INC. | $87.53 | 2022-2025 | |
| Dexcom, INC. | $86.59 | 2022-2023 | Dexcom G7 Gss (161) |
| Allergan, INC. | $72.12 | 2019-2020 | |
| Topcon Healthcare Solutions, INC. | $71.61 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $62.47 | 2022 | |
| Merck Sharp & Dohme LLC | $61.71 | 2019-2022 | |
| Amgen INC. | $57.70 | 2019-2025 | Repatha, Otezla, Otezla |
| Supernus Pharmaceuticals, INC. | $42.05 | 2020 | |
| Insightec,INC | $29.63 | 2025 | Exablate |
| Biohaven Pharmaceutical Holding Company LTD. | $21.58 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $21.38 | 2023 | |
| Sanofi Pasteur INC. | $17.40 | 2019 | |
| Lilly USA, LLC | $13.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.54 | 2019 | |
| Shionogi INC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Uggowitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.